Evidence map›Paper›PMID 41872339›Full record

Observational studyJournal of neurology2026

Eligibility for lecanemab treatment in a French memory clinic setting.

Agathe Vrillon, Karl Götze, Julien Dumurgier, Emmanuel Cognat, Claire Hourrègue, Esteban Munoz-Musat, Théodore Decaix, Jacques Hugon, Janina Estrada, Melanie Sebbagh and 3 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Agathe Vrillon *IHU reConnect, Paris Cité University, Paris, France. agathe.vrillon@aphp.fr.ORCID http://orcid.org/0000-0002-0761-7885
Karl Götze *IHU reConnect, Paris Cité University, Paris, France.
Julien DumurgierCognitive Neurology Center, Lariboisière Fernand Widal Hospital, AP. HP GHU Nord, Paris, France.
Emmanuel CognatIHU reConnect, Paris Cité University, Paris, France.
Claire HourrègueCognitive Neurology Center, Lariboisière Fernand Widal Hospital, AP. HP GHU Nord, Paris, France.
Esteban Munoz-MusatIHU reConnect, Paris Cité University, Paris, France.
Théodore DecaixIHU reConnect, Paris Cité University, Paris, France.
Jacques HugonIHU reConnect, Paris Cité University, Paris, France.
Janina EstradaGeriatric Department, Bretonneau Hospital, AP. HP GHU Nord, Paris, France.
Melanie SebbaghGeriatric Department, Bretonneau Hospital, AP. HP GHU Nord, Paris, France.
Élodie Bouaziz-AmarIHU reConnect, Paris Cité University, Paris, France.
Matthieu LilamandIHU reConnect, Paris Cité University, Paris, France.
Claire PaquetIHU reConnect, Paris Cité University, Paris, France.

Funding

Foundation Alzheimer Young Researcher Program 1310194
6 · The paper itself

Abstract

introductionAnti-amyloid monoclonal antibodies, including lecanemab and donanemab, are now available for the treatment of Alzheimer's disease (AD). Defining real-world patient eligibility and identifying barriers to access are critical for their effective implementation in routine clinical practice.

methodsRetrospective observational multicenter study of patients who underwent CSF AD biomarker testing at Lariboisière Hospital (Paris, France) from 2023 to 2024, assessing lecanemab eligibility using CLARITY AD trial criteria and the French Memory Clinic Federation appropriate use recommendations (AURs) following EMA authorization.

resultsFrom a source population of 3075 patients, 676 underwent CSF testing, and 356 had biomarker-confirmed AD; 315 patients with MRI, APOE status, and MMSE data available (mean age 73.2 ± 8.1 years; 47.8% female; median MMSE 22 [IQR 19-26]) were screened. Using CLARITY AD trial criteria, 90 patients (28.6%) were eligible; low MMSE scores and MRI findings were the most frequent exclusion criteria. French AURs reduced eligibility to 75 patients (23.8%), excluding patients with a CSF A + T - profile and APOE ε4 homozygotes. Eligibility did not differ by age group. Eligibility rates from the entire source population equated to only 2.9% of patients using the CLARITY AD criteria and 2.4% using the French AURs. At follow-up, 34.5% of initially eligible patients no longer met the MMSE eligibility criteria. DISCUSSION: In specialized settings, lecanemab eligibility remained limited, highlighting the need for early AD diagnosis and efficient screening pathways.

Indexed as

Alzheimer DiseaseAntibodies, MonoclonalEligibility DeterminationPatient SelectionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleFranceHumansMaleRetrospective StudiesAmyloid beta-PeptidesAntibodies, MonoclonalBiomarkersAlzheimer’s diseaseAnti-amyloid therapyCSF biomarkersDonanemabLecanemabMemory clinicMild cognitive impairment

Identifiers

PMID41872339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.